BiVictriX CFO appointment

RNS Number : 5744X

BiVictriX Therapeutics PLC

06 January 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Appointment of Glyn Baker as Chief Financial Officer

Alderley Park, 6 January 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Glyn Baker as Chief Financial Officer, in a non-board role.

Glyn has worked in the biotechnology industry for around 20 years, initially as a financial and IT consultant before moving to various senior finance management roles. Most recently, Glyn has been involved in establishing a new Cambridge, UK based start-up in the neurodegenerative disease space.

Prior to this, Glyn was Finance Director of drug discovery company Inflazome Ltd ("Inflazome"). In his role there, Glyn successfully managed a €40m Series B investment round and arranged a US$20m venture debt facility with Oxford Finance LLP based in Boston in the US. In 2020, Inflazome was bought by Roche for an upfront payment of US$450m plus substantial milestones. Glyn was part of the Inflazome board sub-committee managing relationships with investors, potential exit partners and a range of intermediaries.

Before Glyn joined Inflazome he was the CFO of TwistDx Ltd ("TwistDx"). TwistDx was sold to Alere, Inc. in March 2010, which was subsequently acquired by Abbott Laboratories, Inc. in February 2016.

Ms Laura Brogden, the Company's Financial Controller, will remain with BiVictriX for a period of three months to ensure an orderly handover of responsibilities to Glyn Baker.

Tiffany Thorn, Chief Executive of BiVictriX, commented: "We are delighted to welcome Glyn Baker to BiVictriX as Chief Financial Officer. Glyn has amassed significant expertise in Finance and M&A over the last 20 years with some impressive accomplishments. This  knowledge, coupled with his contacts, will be invaluable as we look to grow our business and progress the development of our Bi-Cygni® therapeutics."

Glyn Baker, BiVictriX's new Chief Financial Officer, added: "I was particularly attracted to BiVictriX due to the quality of the science, the leadership team and the Board of directors. I look forward to supporting Tiffany and the broader team as the Company progresses the development of its key work programmes."

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Ashley Tapp, Suki Virji Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com    

 

END

 

 

MSCDGGDBXUGDGDU